The global axial spondyloarthritis (axSpA) management market, valued at USD 4.22 billion in 2022, is anticipated to expand steadily, projected to reach approximately USD 7.3 billion by 2033. This growth, expected at a CAGR of 5.1% from 2023 to 2033, is driven by a rising prevalence of axSpA and the increasing demand for efficient treatment …